Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL)
<p style="text-align:justify;"> <b>Background:</b> Diffuse large B-cell lymphoma (DLBCL) comprises 31% of lymphomas in the United States. Although it is an aggressive type of lymphoma, 40% to 50% of patients are cured with treatment. The study objectives were to identify...
| Main Authors: | , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
BioMed Central
2010
|
| _version_ | 1797086460796469248 |
|---|---|
| author | Griffiths, R Gleeson, M Knopf, K Danese, M |
| author_facet | Griffiths, R Gleeson, M Knopf, K Danese, M |
| author_sort | Griffiths, R |
| collection | OXFORD |
| description | <p style="text-align:justify;"> <b>Background:</b> Diffuse large B-cell lymphoma (DLBCL) comprises 31% of lymphomas in the United States. Although it is an aggressive type of lymphoma, 40% to 50% of patients are cured with treatment. The study objectives were to identify patient factors associated with treatment and survival in DLBCL.<br/><br/> <b>Methods:</b> Using Surveillance, Epidemiology, and End Results (SEER) registry data linked to Medicare claims, we identified 7,048 patients diagnosed with DLBCL between January 1, 2001 and December 31, 2005. Patients were followed from diagnosis until the end of their claims history (maximum December 31, 2007) or death. Medicare claims were used to characterize the first infused chemo-immunotherapy (C-I therapy) regimen and to identify radiation. Multivariate analyses were performed to identify patient demographic, socioeconomic, and clinical factors associated with treatment and with survival. Outcomes variables in the survival analysis were all-cause mortality, non-Hodgkin's lymphoma (NHL) mortality, and other/unknown cause mortality.<br/><br/> <b>Results:</b> Overall, 84% (n = 5,887) received C-I therapy or radiation treatment during the observation period: both, 26%; C-I therapy alone, 53%; and radiation alone, 5%. Median age at diagnosis was 77 years, 54% were female, 88% were white, and 43% had Stage III or IV disease at diagnosis. The median time to first treatment was 42 days, and 92% of these patients had received their first treatment by day 180 following diagnosis. In multivariate analysis, the treatment rate was significantly lower among patients ≥ 80 years old, blacks versus whites, those living in a census tract with ≥ 12% poverty, and extra-nodal disease. Blacks had a lower treatment rate overall (Hazard Ratio [HR] 0.77; P < 0.001), and were less likely to receive treatment within 180 days of diagnosis (Odds Ratio [OR] 0.63; P = 0.002) than whites. In multivariate survival analysis, black race was associated with higher all-cause mortality (HR 1.24; P = 0.01) and other/unknown cause mortality (HR 1.35; P = 0.01), but not mortality due to NHL (HR 1.16; P = 0.19).<br/><br/> <b>Conclusions:</b> In elderly patients diagnosed with DLBCL, there are large differences in treatment access and survival between blacks and whites. </p> |
| first_indexed | 2024-03-07T02:22:21Z |
| format | Journal article |
| id | oxford-uuid:a461714b-3d5d-48e5-afb5-8edba36bb6d2 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T02:22:21Z |
| publishDate | 2010 |
| publisher | BioMed Central |
| record_format | dspace |
| spelling | oxford-uuid:a461714b-3d5d-48e5-afb5-8edba36bb6d22022-03-27T02:33:28ZRacial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL)Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:a461714b-3d5d-48e5-afb5-8edba36bb6d2EnglishSymplectic Elements at OxfordBioMed Central2010Griffiths, RGleeson, MKnopf, KDanese, M <p style="text-align:justify;"> <b>Background:</b> Diffuse large B-cell lymphoma (DLBCL) comprises 31% of lymphomas in the United States. Although it is an aggressive type of lymphoma, 40% to 50% of patients are cured with treatment. The study objectives were to identify patient factors associated with treatment and survival in DLBCL.<br/><br/> <b>Methods:</b> Using Surveillance, Epidemiology, and End Results (SEER) registry data linked to Medicare claims, we identified 7,048 patients diagnosed with DLBCL between January 1, 2001 and December 31, 2005. Patients were followed from diagnosis until the end of their claims history (maximum December 31, 2007) or death. Medicare claims were used to characterize the first infused chemo-immunotherapy (C-I therapy) regimen and to identify radiation. Multivariate analyses were performed to identify patient demographic, socioeconomic, and clinical factors associated with treatment and with survival. Outcomes variables in the survival analysis were all-cause mortality, non-Hodgkin's lymphoma (NHL) mortality, and other/unknown cause mortality.<br/><br/> <b>Results:</b> Overall, 84% (n = 5,887) received C-I therapy or radiation treatment during the observation period: both, 26%; C-I therapy alone, 53%; and radiation alone, 5%. Median age at diagnosis was 77 years, 54% were female, 88% were white, and 43% had Stage III or IV disease at diagnosis. The median time to first treatment was 42 days, and 92% of these patients had received their first treatment by day 180 following diagnosis. In multivariate analysis, the treatment rate was significantly lower among patients ≥ 80 years old, blacks versus whites, those living in a census tract with ≥ 12% poverty, and extra-nodal disease. Blacks had a lower treatment rate overall (Hazard Ratio [HR] 0.77; P < 0.001), and were less likely to receive treatment within 180 days of diagnosis (Odds Ratio [OR] 0.63; P = 0.002) than whites. In multivariate survival analysis, black race was associated with higher all-cause mortality (HR 1.24; P = 0.01) and other/unknown cause mortality (HR 1.35; P = 0.01), but not mortality due to NHL (HR 1.16; P = 0.19).<br/><br/> <b>Conclusions:</b> In elderly patients diagnosed with DLBCL, there are large differences in treatment access and survival between blacks and whites. </p> |
| spellingShingle | Griffiths, R Gleeson, M Knopf, K Danese, M Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL) |
| title | Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL) |
| title_full | Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL) |
| title_fullStr | Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL) |
| title_full_unstemmed | Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL) |
| title_short | Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL) |
| title_sort | racial differences in treatment and survival in older patients with diffuse large b cell lymphoma dlbcl |
| work_keys_str_mv | AT griffithsr racialdifferencesintreatmentandsurvivalinolderpatientswithdiffuselargebcelllymphomadlbcl AT gleesonm racialdifferencesintreatmentandsurvivalinolderpatientswithdiffuselargebcelllymphomadlbcl AT knopfk racialdifferencesintreatmentandsurvivalinolderpatientswithdiffuselargebcelllymphomadlbcl AT danesem racialdifferencesintreatmentandsurvivalinolderpatientswithdiffuselargebcelllymphomadlbcl |